Efficacy of systemic administration of irinotecan against neuroblastoma xenografts

Clinical Cancer Research

Volumn 3, Issue 3, 1997, Pages 423-431

  Thompson, Joyce ^a   Zamboni, William C ^a   Cheshire, Pamela J ^a   Lutz, Lois ^a   Luo, Xiaolong ^a   Li, Yulan ^a   Houghton, Janet A ^a   Stewart, Clinton F ^a   Houghton, Peter J ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL DIVISION; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED CBA; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; THYMECTOMY; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030935790     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 54: 665-697, 1985.
2. Wang, J. C. Recent studies of DNA topoisomerases. Biochim. Biophys. Acta, 909: 1-9, 1987.
3. Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K., and Hertzberg, R. P. Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J, Med. Chem., 34: 98-107, 1990.
4. Gottlieb, J. A., and Luce, J. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep., 56: 103-105, 1972.
5. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T., and Block, J. B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep., 54: 461-470, 1970.
6. Moertel, C. G., Schutt, A. J., Reitemeier, R. J., and Hahn, R. G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56: 95-101, 1972.
7. Houghton, P. J., Cheshire, P. J., Myers, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
8. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-1-carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res., 47: 5944-5947, 1987.
9. Matsuzaki, T., Yokokura, T., Mutai, M., and Tsuruo, T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin. CPT-11, in mice. Cancer Chemother Pharmacol 21: 308-312, 1988.
10. Bissery, M. C., Mathieu-Boué, A., and Lavelle, F. Preclinical evaluation of CPT-11, a camptothecin derivative. Proc. Am. Assoc. Cancer Res., 33: 402, 1991.
11. Bissery, M. C., Mathieu-Boué, A., and Lavelle, F. Experimental activity of CPT-11 in vitro and in vivo. Ann. Oncol., 3 (Suppl. 1): 93, 1992.
12. Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T., and Matsumoto, K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28: 192-198, 1991.
13. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boué, A., and Houghton, J. A . Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[l-piperidino]-l-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53: 2823-2829, 1993.
14. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II, Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
15. Tsuruo, T., Matsuzaki, T., Matsushita, M., Saito, H., and Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol., 21: 71-74, 1988.
16. Wiseman, L. R., and Markham, A. Irinotecan: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs, 52: 602-623, 1996.
17. Masuda, N., Fukuoka, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K., and Takada, M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10: 1225-1229, 1992.
18. Fujita, A., Takabatake, H., Tagaki, S., and Sekine, K. Pilot study of irinotecan in refractory small cell lung cancer. Can To Kagaku Ryoho, 22: 889-893, 1995.
19. Ohno, R,. Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ichimaru, M., Sakai, Y., Oguro, M., Ito, Y., Morishima, Y., Yokomaku, S., and Ota, K. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol., 8: 1907-1912, 1990.
20. Fukuoka, M., Niitanim, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S., and Taguchi, T. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10: 16-20, 1992.
21. Fukuoka, M., and Masuda, N. Clinical studies of irinotecan and in combination with cisplatin. Cancer Chemother. Pharmacol., 34 (Suppl.): S105-S111, 1994.
22. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., Ogawa, N., and the CPT-11 Gastrointestinal Cancer Study Group. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol., 11: 909-913, 1993.
23. Nishimura, G., Satou, T., Yoshimitsu, Y., Kurosaka, Y., Fujimura, T., Sugiyama, K., and Yonemura, Y. Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer. Gan To Kagaku Ryoho, 22: 93-97, 1995.
24. Rougier, P., Culine, S., Bugat, R., Brunet, P., Douillard, J. Y., Ychou, M., Many, M., Bonneterre, J., Ganem, G., Seitz, J. F., Negrier, S., Namer, M., Conroy, T., Burki, F., Shearer, J. P., Mathieu-Boué, A., Mahjoubi, M., and Herait, P. Multicentric phase II study of first line CPT-11 (irinotecan) in advanced colorectal cancer (CRC): preliminary results. Proc. Am. Soc. Clin. Oncol., 13: A585, 1994.
25. Rothenberg, M. L., Eckardt, J. R., Burris, H. A., Nelson, J., Kuhn, J. G., Chen, S. F., Hilsenbeck, S. G., Clark, G. M., Fields, S. M., Rodriguez, G. I., Weiss, G. R., Smith, L. S., Thurman, A. M., Eckhardt, S. G., Rinaldi, D. A., Perez, E., and Von Hoff, D. D. Irinotecan (CPT-11) as second-line therapy for patients with 5-FU-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol., 13: 200, 1994.
26. Pilot, H. C., Wender, D., O'Connell, M. J., Wieand, H. S., and Mailliard, J. A. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Proc. Am. Soc. Clin. Oncol., 13: 197, 1994.
27. Burris, H. A., Rothenberg, M. L., Kuhn, J. G., and Von Hoff, D. D. Clinical trials with the topoisomerase I inhibitors. Semin. Oncol., 19: 663-669, 1993.
28. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J,., Vokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucoronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
29. Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Takifuji, N., Nakagawa, K., Tamanoi, M., Nitta, T., Hirashima, T., Negoro, S., and Takada, M. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br. J. Cancer, 68: 777-782, 1993.
30. Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Nakagawa, K., Hirashima, T., Tamanoi, M., Nitta, T., Yana, T. Negoro, S., Takifuji, N., and Takada, M. Phase I study of irinotecan and cisplatin with granulocyte colony stimulating factor support for advanced non-small cell lung cancer. J. Clin. Oncol., 12: 90-96, 1994.
31. Shinkai, T., Arioka, H., Kunikane, H., Eguchi, K., Sasaki, Y., Tamura, T., Ohe, Y., Oshita, F., Nishio, M., Karato, A., Okamoto, H., Nakashima, H., Ohmatsu, H., Shiraishi, J., Nomura, N., and Saijo, N. Phase I clinical trial of irinotecan (CPT-1I), 7-ethyl-10-[4-(1-piperidino)-l-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose vindesine in advanced non-small cell lung cancer. Cancer Res., 54: 2636-2642, 1994.
32. Shimada, Y., Sasaki, Y., Sugano, K., Shirao, K., Kondo, H., Yokota, T., Saito, D., Tamura, T., Ohe, Y., Shinkai, T,. Eguchi, K., Saijo, N., Shintani, S., Nitta, T., Yana, H., and Takada, M. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer. Proc. Am. Assoc. Clin. Oncol., 12: 196, 1993.
33. Negoro, S., Fukuoka, M., Masuda, N., Kusunoki, Y., Matsui, K., Kudoh, S., Takifuji, N., Nakagawa, K., Hirashima, T., Tamanoi, M., Nitta, T., Yana, H., and Takeda, M. Phase I study of irinotecan (CPT-11) and etoposide (E) with G-CSF in advanced lung cancer. Proc. Am. Assoc. Clin. Oncol., 12: 133, 1993.
34. Masuda, N., Fukuoka, M., Kudoh, S., Matsui, K., Kusunoki, Y., Takada, M., Nakagawa, K., Hiroshima, T., Tsukada, H., Yana, T., Yoshikawa, A., Kuba, A., Matsura, E., Nitta, T., Takifuji, N., Terakawa, K., and Negoro, S. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J. Clin. Oncol., 12: 1833-1841, 1994.
35. Rosen, E. M., Cassady, J. R., Frantz, C. N., Kretschmar, C. S., Levey, R., and Sallan, S. E. Neuroblastoma: the joint center for radiation therapy/Dana-Farber Cancer Institute/Children's Hospital Experience. J. Clin. Oncol., 2: 719-732, 1984.
36. Kretschmar, C. S., Frantz, C. N., Rosen, E. M., Cassady, J. R., Levey, R., and Sallan, S. E. Improved prognosis for infants with stage IV neuroblastoma. J. Clin. Oncol., 2: 799-803, 1984.
37. Shafford, E. A., Rogers, D. W., and Pritchard, J. Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J. Clin. Oncol., 2: 742-747, 1984.
38. Finkelstein, J. Z., Klemperer, M. R., Evans, A., Bernstein, I., Leikin, S., McCreadie, S., Grosfeld, J., Hittle, R., Weiner, J., Sather, H., and Hammond, D. Multiagent chemotherapy for children with metastatic neuroblastoma: a Report Childrens Cancer Study Group. Med. Pediatr. Oncol., 6: 179-188, 1979.
39. Nitschke, R., Cangir, A., Crist, W., and Berry, D. H. Intensive chemotherapy for metastatic neuroblastoma: a SWOG study. Med. Pediatr. Oncol., 8: 281-288, 1980.
40. Frantz, C. N., Gelber, R. D., and Belli, J. A. Aggressive treatment of neuroblastoma. In: C. Raybaud (ed.), Pediatric Oncology, Proceedings of the XIII International Meeting of the Society of Pediatric Oncology, p. 175. Marseille, France: Excerpta Medica, 1981.
41. Komuro, H., Li, P., Tsuchida, Y., Yokomori, K., Nakajima, K., Aoyama, T., Kaneko, M., and Kaneda, N. Effects of CPT11 (a unique DNA topoisomerase 1 inhibitor) or a highly malignant xeno-transplanted neuroblastoma. Med. Pediatr. Oncol., 23: 487-492, 1994.
42. Vassal, G., Morizet, J., Bissery, M-C., Benard, J., Boland, I., Ardouin, P., Mathieu-Boué, A., and Gouyette, A. Activity of the camptothecin analogue CPT-11 (Irinotecan) against neuroblastoma xenografts. Med. Pediatr. Oncol., 23: 207, 1994.
43. Pratt, C. B., Stewart, C., Santana, V. M., Bowman, L., Furman, W., Ochs, J., Marina, N., Kuttesch, J., Heideman, R., Sandlund, J., Avery, L., and Meyer, W. H. Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol., 3: 539-543, 1994.
44. Kretschmar, C., Kletzel, M., Murray, K., Joshi, V., Smith, E., Pao, R., and Castleberry, R. Upfront Phase II therapy with Taxol and topotecan in untreated children (>365 days) with disseminated (INSS stage 4) neuroblastoma: a Pediatric Oncology Group study. Med. Pediatr. Oncol., 25: 243, 1995.
45. Chabot, G. G., Gouyette, A., and Bissery, M. C. Tumor influence on pharmacokinetics of the camptothecin analogue irinotecan (CPT-11) and active metabolite SN-38 in mice. Proc. Am. Assoc. Cancer Res., 35: 432, 1994.
46. Houghton, P. J., Houghton, J. A., Myers, L., Cheshire, P. J., Howbert, J. J., and Grindey, G. B. Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother. Pharmacol., 25: 84-88, 1989.
47. Rivory, L. P., and Robert, J. Reversed-phase high-performance liquid chromatography method for the simultaneous quantification of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J. Chromatog. Biol. Biomed. Appl., 661: 133-141, 1994.
48. D'Argenio, D. Z., and Schumitzky, A. ADAPT II Users Guide. University of Southern California, Los Angeles. Biomedical Simulations Resource, 1990.
49. Kalbfleisch, J. D., and Prentice, R. L. The Statistical Analysis of Failure Time Data, pp. 143-161. New York: John Wiley & Sons, 1980.
50. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
51. Lehman, E. Nonparametrics: Statistical Methods Based on Ranks. San Francisco: Holden-Day, Inc., 1975.
52. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., and Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (Washington DC), 224: 1121-1124, 1984.
53. Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., and Hammond, D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med., 313: 1111-1116, 1985.